OKUR - OnKure Therapeutics Quarterly EPS earnings growth

Corporate emblem and logo of OnKure (OKUR)

The quarterly earnings per share trend for OnKure Therapeutics Inc (OKUR) demonstrates the impact of patents on targeted inhibitors, which have created a defensive barrier for margins. The 67.70 mark records this metric, highlighting the business's financial status. Formula development has been delegated to external contractors, while experienced scientists manage the biotech operations, transparently allocating venture investments into clinical phases.

OnKure Therapeutics (OKUR) Earnings per share growth in annualized terms for the last twelve months: for the period 10/08/2024 - 11/18/2026

OKUR (OnKure Therapeutics, Inc.): analytical breakdowns and indicator data

- market value and analyst target forecast:
Initial company analysis:OnKure Therapeutics Inc
Manufactured product of OnKure Therapeutics

For OnKure Therapeutics Inc (OKUR), whose revenue is constrained by strict clinical trial protocols and FDA decisions, this indicator reflects the monetization efficiency of targeted oncology. The quarterly EPS growth trend measures the percentage change in net income per share relative to the previous period, allowing investors to assess the sustainability of the business model and promptly identify the risk of profit stagnation during a shift in the regulatory cycle.

Who OnKure Therapeutics Inc competes with

ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Group AAPG|Quarterly EPS earnings growth CGON|Quarterly EPS earnings growth UroGen Pharma Ltd (URGN)|Quarterly EPS earnings growth BCAX (Bicara Corp)|Personalis Genomics (PSNL) - Earnings per share growth in annualized terms for the last twelve months|Erasca Oncology - Quarterly EPS earnings growth|DCTH: Year-over-year earnings per share growth for the last twelve months|YMAB: Quarterly EPS earnings growth|Aura Bio (AURA) - Quarterly EPS earnings growth|CADL (Candel Therapeutics Inc.) - Quarterly EPS earnings growth|ARAY: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SLS (SELLAS Life Sciences Group, Inc.)|Year-over-year earnings per share growth rate for the last twelve months ACTU|Citius Oncology - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months HURA|TARA: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Fate Pharma|Aadi Bioscience Inc (WHWK) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months TScan (TCRX)|Year-over-year net earnings per share growth for the last 12 months CSBR|xbiotech.com (XBIT) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months cel-sci.com (CVM)|OSTX - Earnings per share growth in annualized terms for the last twelve months|Radiopharm Theranostics - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months ARTV|ANL - Year-over-year earnings per share growth for the last twelve months|VERU - Quarterly EPS earnings growth|Tempest Therapeutics, Inc. (TPST) - Year-over-year earnings per share growth for the last twelve months|XLO: Year-over-year earnings per share growth rate for the last twelve months|RENB (Renovaro Biosciences) - Quarterly EPS earnings growth|MURA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months KAPA (Kairos Pharma Ltd)|Quarterly EPS earnings growth CytoMed (GDTC)|Year-over-year earnings per share growth for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|Tharimmune Corporation - Quarterly EPS earnings growth|ADVB (advanbiomed.com) - Year-over-year earnings per share growth for the last 12 months|Genprex, Inc (GNPX) - Year-over-year earnings per share growth for the last twelve months|CLDI: Year-over-year earnings per share growth rate for the last twelve months|SBFM (Sunshine Biopharma, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months XBIO (Xenetic Biosciences)|Quarterly EPS earnings growth SLRX|Purple Biotech - Year-over-year earnings per share growth for the last 12 months|American Oncology Network - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT - Year-over-year earnings per share growth for the last twelve months|Elevation Oncology (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)